title: IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
abstract: OBJECTIVE
  To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients.
  
  
  METHODS
  768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay.
  
  
  RESULTS
  In the discovery stage, 22 SNPs were nominally significant. IL1B rs1143623 (p = 0.011) and EEF1A1P11-RPL7P9 rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA1c in the replication stage.
  
  
  CONCLUSIONS
  IL1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Di
authors.initials: D
authors.lastname: Xiao
authors.affiliation: Department of Endocrinology, The People's Hospital of Peking University, Beijing 100044, People's Republic of China.
authors.forename: Si-Min
authors.initials: SM
authors.lastname: Zhang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Ji-Ye
authors.initials: JY
authors.lastname: Yin
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.
authors.forename: Wei-Jing
authors.initials: WJ
authors.lastname: Gong
authors.affiliation: The Maternal & Child Health Hospital of Hunan Province, Changsha 410008, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.
authors.forename: Xiao-Jing
authors.initials: XJ
authors.lastname: Xu
authors.affiliation: Institute of Nutrition Science of Shanghai School for Biological Sciences, Chinese Academy of Sciences, Shanghai 20031, People's Republic of China.
authors.forename: Xu
authors.initials: X
authors.lastname: Lin
authors.affiliation: Department of Endocrinology, The People's Hospital of Peking University, Beijing 100044, People's Republic of China.
authors.forename: Li-Nong
authors.initials: LN
authors.lastname: Ji
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.
authors.forename: Rang-Ru
authors.initials: RR
authors.lastname: Liu
authors.affiliation: Department of Pharmacy, The Huaihua Third People's Hospital, Huaihua 418000, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Tang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Hong-Hao
authors.initials: HH
authors.lastname: Zhou
authors.affiliation: Department of Endocrinology, The People's Hospital of Peking University, Beijing 100044, People's Republic of China.
authors.forename: Xue-Yao
authors.initials: XY
authors.lastname: Han
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People's Republic of China.|Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, People's Republic of China.
authors.forename: Zhao-Qian
authors.initials: ZQ
authors.lastname: Liu
mesh_terms: D000368:Aged; D044466:Asian People; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005838:Genotype; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000235:genetics*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D050177:Overweight / Q000150:complications*; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D053583:Interleukin-1beta; D008687:Metformin; C508585:IL1B protein, human
keywords: SNP; Type 2 diabetes mellitus; glucose-lowing efficacy; metformin; obese; overweight; pharmacogenomics